Business Context and Reporting Period
This Form 8-K is filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on August 13, 2024. The filing serves to announce the Company's financial results for the second quarter ended June 30, 2024, as detailed in the press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the input content.
Material Changes
No material changes versus the prior comparable period are described in the provided text. The document solely references the issuance of the Q2 2024 results without detailing specific variances or trends.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the correct registrant name is Ocuphire Pharma, Inc. (Ticker: OCUP), as the request metadata incorrectly listed "Opus Genetics, Inc."
- Review Exhibit 99.1 (the Press Release dated August 13, 2024) for actual financial figures, as they are absent from the Form 8-K text.
- Confirm the reporting period is the quarter ended June 30, 2024.
- Note that the financial data in this filing is "furnished" and not "filed" under Section 18 of the Exchange Act.